Validation of Chlamydia Diagnostic Codes in TriNetX US EHR Data
Investigational Study on Chlamydia Diagnostic Codes Using Electronic Health Records (EHR) Data
Study Overview
This study is a pharmacoepidemiologic method study based on the secondary use of pre-existing data that examines whether TriNetX, a global health research network encompassing a worldwide electronic health record (EHR), database in the US is an appropriate real-world data (RWD) source for conducting chlamydia-related research to support the chlamydia trachomatis (CT) messenger Ribonucleic acid (mRNA) vaccine program.
There are two primary objectives for this study:
- To determine the validity of ICD, Tenth Revision, Clinical Modification (ICD-10-CM) diagnostic codes to identify patients with chlamydial infections using TriNetX EHR data in the US
- To describe screening or diagnostic testing and treatment patterns in patients with chlamydia using TriNetX EHR data in the US
There are also two secondary objectives for this study:
- To explore the feasibility of developing a modified algorithm for identifying patients with chlamydia applicable for Merative MarketScan Commercial Claims and Encounters (CCAE) database based on the findings from the primary objectives
- To compare patient characteristics, use of screening or diagnostic testing, and treatment patterns among patients with chlamydia between TriNetX EHR data and the MarketScan CCAE data in the US
Eligibility Criteria
You may be eligible for this study if you meet the following criteria:
- Conditions: Chlamydial Infections
-
Age: 14 years - 44 years
-
Gender: All
Inclusion Criteria for Primary Objectives:
- Patients with an ICD-10-CM diagnosis of chlamydia documented in their EHR OR patients with a nucleic acid amplification test (NAAT) result for chlamydia (either positive or negative) during the study period. The index date is the date of the first-recorded diagnosis code, or the date of the first-recorded NAAT result when no diagnosis code for chlamydia exists.
- Patients with at least one visit within 30 days both before and after their index date.
Exclusion Criteria for Primary Objectives:
- Patients with no documented ICD-10-CM diagnosis for chlamydia who possessed unknown laboratory test results for chlamydia during the study period (removed from ICD validation assessment in primary analysis).
- Patients with an ICD-10-CM diagnosis without a corresponding laboratory test (removed from ICD validation assessment in primary analysis).
Note: The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.
This study investigates the use of electronic health records (EHR) to validate diagnostic codes for chlamydia infections. The purpose is to determine if the TriNetX database can be a reliable source for chlamydia-related research. The study aims to assess the accuracy of ICD-10-CM codes for identifying chlamydia cases and to analyze testing and treatment patterns in the US.
The study procedures involve analyzing existing patient data from the TriNetX EHR network. Researchers will look at patients who have a documented ICD-10-CM diagnosis of chlamydia or have undergone nucleic acid amplification tests (NAAT) for the infection. The study will also compare data from TriNetX with the MarketScan database to explore potential algorithm improvements for identifying chlamydia cases.
- Who can participate: Adults with a documented ICD-10-CM diagnosis of chlamydia or who have undergone a NAAT for chlamydia during the study period can participate, provided they have at least one medical visit within 30 days before and after the diagnosis or test date.
- Study details: Participants will not undergo any new procedures as part of this study. Instead, researchers will use existing EHR data to analyze diagnostic codes and treatment patterns for chlamydia.
Find a study site near you
,
Send a message
Enter your contact details to connect with study team
Primary Contact
